Blockchain Registration Transaction Record

CNS Pharmaceuticals Transfers Orphan Drug Designation for TPI 287 with Positive Results

CNS Pharmaceuticals announces successful transfer of Orphan Drug Designation for TPI 287, showing promising results in Phase 1 trial. Learn more about the company's advancements in brain cancer treatment.

CNS Pharmaceuticals Transfers Orphan Drug Designation for TPI 287 with Positive Results

This news matters as it signifies a significant milestone for CNS Pharmaceuticals in advancing treatment options for brain and CNS cancers. The successful transfer of Orphan Drug Designation for TPI 287 demonstrates the potential for improved therapies in glioblastoma and other neurodegenerative diseases.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x7e2fdcbf8a518a04c78d7ddf0101ebfd0fffd68668be3f76099b413affe5a03f
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintswimm1XW-f8998628d940bd6c5e96b64f9fcd37be